Imagine a world. where doubt about cancer diagnostics and treatment is a thing of the past. A world where patients no longer need to wait for clarity. A world where patients will not get unnecessary surgeries. A world where cancer is no longer scary, because it is found early enough to be treated easily. Imagine a world in which cancer is obvious. Worldwide, the incidence of cancer is growing, as life expectancy increases. Current imaging tools used for cancer detection in hollow organs have their limitations as they are not suitable to provide the necessary information. In particular, information on the tissue structure on mm scale at high resolution is missing. Scinvivo develops an innovative imaging platform which allows visualization of both the superficial and the profound tissue structure in real time during a standard endoscopic examination. An incredible resolution of only a few micrometers allows the detection of tumors very early. The first use case for this technology is bladder cancer as the medical need for better imaging tools is very high in this application. It is Scinvivos vision that its technology will become the standard of care in bladder cancer diagnosis and treatment by providing urologists with our Lumante OCT (Optical Coherence Tomography) platform for image guided diagnosis and therapy. Scinvivo firmly believes that unnecessary surgeries for bladder cancer can be prevented by providing real-time diagnostic information to enable fast treatment stratification, and facilitate the move towards treatment in the ambulatory setting (e.g. laser treatment). Such approach will make bladder cancer treatment more accurate, fast and personalized. We will improve people's lives by enabling fast and personalized diagnosis and treatment, preventing unnecessary surgeries and saving costs of care. Within this project, we want to further develop our Lumante imaging platform and introduce it to the US and EU market.

Photonics is a key enabling technology in the realization of modern medical devices with applications ranging from diagnostics to personalised monitoring and therapeutics. Characteristic nature of both photonics and medical applications is high diversity. Therefore, the more widespread use of photonics technologies in scattered ecosystems presents major challenges for the technological values chains comprising end-user companies and manufacturers. In conjunction with highly regulated validation and production processes, the timespan from the proof-of-concept to product launch takes years causing high costs. Relying on existing pilot line concept, PhotonMed aims at accelerated uptake of the latest photonics technologies in medical device applications. PhotonMed project is applied to continuously renew the technology offering of photonics pilot line and to invite new members and countries to join the ecosystem. Within research-oriented PhotonMed project RTOs and industrial parties can develop their technology offering while the end-user companies get matured demonstrators based on the latest research results.